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Evaluation of a Rhodomyrtus tomentosa 
ethanolic extract for its therapeutic potential 
on Staphylococcus aureus infections using 
in vitro and in vivo models of mastitis
Auemphon Mordmuang1,3, Eric Brouillette2, Supayang Piyawan Voravuthikunchai1* and François Malouin2* 
Abstract 
An ethanolic extract from Rhodomyrtus tomentosa leaves (RTL) was studied as a natural alternative to control Staphy-
lococcus aureus, which is an important pathogen responsible for bovine mastitis. The minimal inhibitory concentra-
tions (MICs) of the RTL extract and of rhodomyrtone, a pure compound isolated from the plant, were determined by a 
microdilution method. Rhodomyrtone and the RTL extract exhibited antibacterial activity against S. aureus, including 
its persistent phenotype (SCV: small-colony variant) and a biofilm hyperproducer strain, with MICs of 0.25–0.5 and 
8–16 µg/mL, respectively. Time-kill kinetics showed a strong bactericidal activity for both the RTL extract- and rhod-
omyrtone-treated bacteria at 2 × MIC as early as 4 h post-exposure. An additive effect of the extract at 0.5 × MIC was 
observed in a combination with oxytetracycline or pirlimycin against S. aureus by showing a 64- to 128-fold reduction 
in antibiotic MICs. Moreover, the RTL extract significantly decreased the number of intracellular SCVs inside bovine 
mammary epithelial cells. However, the extract or its combination with pirlimycin only slightly improved the activity 
of pirlimycin against the bacterial colonization of mouse mammary glands. In vitro MICs determined in the presence 
of casein indicated that the limited activity of the RTL extract in the murine model of mastitis could be linked to neu-
tralization of active components by milk proteins. While the RTL extract showed interesting antibacterial properties 
in vitro, to be considered as an alternative to antibiotics in dairy farms, formulation studies are needed to cope with 
the observed reduction of activity in vivo.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Bovine mastitis caused by Staphylococcus aureus is an 
important problem in the dairy industry worldwide. 
The bacterium is associated with subclinical and clini-
cal bovine mastitis, that can spread contagiously to other 
animals in the herd [1–3]. S. aureus produces many 
toxins including extracellular hydrolytic enzymes that 
can impair host defenses and damage mammalian cells 
and tissues but one of the crucial functional mechanisms 
of S. aureus virulence is its ability to invade, persist and 
replicate inside host cells [4, 5].
Staphylococcus aureus strain Newbould, a prototypic 
strain isolated from a case of clinical bovine masti-
tis and its laboratory-derived hemB-deleted mutant 
strain, a small colony variant (SCV), have been exten-
sively studied for their phenotype and role in persis-
tent infections [6, 7]. The ability of SCVs to persist in 
phagocytic cells or in nonprofessional phagocytes such 
as fibroblasts, endothelial cells, and epithelial cells has 
been established [8–10]. Internalization of bacteria into 
host cells can facilitate evasion from the host immune 
system and is a phenomenon that is associated with 
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the chronic or recurrent manifestation of the disease. 
Switching from the normal to the SCV phenotype and 
vice versa is believed to be part of the natural infection 
process for S. aureus [11]. In addition, clinical SCVs 
have been frequently isolated following antibiotic pres-
sure [12, 13]. SCVs have been detected in persistent 
bovine mastitis [14] and a therapeutic solution for S. 
aureus bovine mastitis needs to be successful against 
the SCV phenotype.
Antibacterial therapies are being challenged by the 
widespread development of bacterial resistance. Bac-
terial strains designated as methicillin-resistant S. 
aureus (MRSA) have been isolated from bovine milk 
[15]. In addition to the occurrence of antibiotic resist-
ant strains, which may be spread from cow to cow by 
contaminated equipment or in the community by farm 
workers, treatment of intramammary infections using 
antibiotics increases consumer concerns about food-
related health risks and problems associated with drug 
residues in milk. Therefore, attempts of using natural 
alternatives to antibiotics for treatment of mastitis have 
been made, in order to minimize the usage of tradi-
tional antibiotics or chemical agents in the animal food 
industry [16]. The reduction of antibiotic use and dis-
covery of alternatives in agri-food sectors where anti-
biotics are heavily used should directly benefit human 
health as it may limit and prevent the development of 
antibiotic resistance.
Rhodomyrtus tomentosa is a medicinal plant belong-
ing to the Myrtaceae family and an ethanolic leaf extract 
of the plant was previously shown to have an antibacte-
rial activity against Gram-positive bacteria including S. 
aureus, coagulase-negative staphyloccocci and Strepto-
coccus spp., that are widely found as causative agents of 
bovine mastitis [17]. In addition, rhodomyrtone, a pure 
compound isolated from this plant, has demonstrated a 
strong inhibitory effect against S. aureus similar to that 
obtained with vancomycin, an important anti-S. aureus 
drug in human medicine [18]. Recently, we have reported 
that a R. tomentosa ethanolic leaf (RTL) extract affected 
S. aureus cell surface properties by increasing its hydro-
phobicity and consequently disturbed bacterial adhesion 
and invasion into host cells in an ex  vivo bovine udder 
epidermal tissue model [19].
The use of a plant extract that is easy to produce 
could facilitate its introduction as a novel natural 
alternative to antibiotics. In the present study, the 
aims were to determine the effect of the RTL extract 
on the ability of S. aureus to invade bovine mammary 
epithelial cells, to specifically include S. aureus SCVs 
among the studied bacterial targets, and to investi-
gate any possible synergistic effects the RTL extract 
could have with traditional antibiotics, in order to 
improve their therapeutic efficacy or to reduce the 
amounts needed. A mastitis-relevant mouse S. aureus 
intramammary infection model was used to evaluate 
in vivo efficacy.
Materials and methods
Bacterial strains and growth conditions
Staphylococcus aureus strains used in this study 
included Newbould (ATCC 29740) and its laboratory-
derived isogenic small colony variant (SCVs) coun-
terpart (∆hemB) that was described before [6]. Also 
included was strain SHY97-3906 that was isolated 
from a case of clinical bovine mastitis [20]. Other iso-
lates were selected from the Mastitis Pathogen Culture 
Collection (MPCC) belonging to the Canadian bovine 
mastitis and milk quality research network (CBMQRN, 
St-Hyacinthe, QC, Canada), as described in detail in 
Reyher et  al. [2]. These isolates included one bovine 
methicillin-resistant S. aureus (MRSA strain 1158, spa 
type t451, barcode 1081-2464), one biofilm hyperpro-
ducer (strain 2117, spa type t13401, barcode 1070-
5001) evidenced in a previous study [21], as well as 
strains 2236 (spa type t257, barcode 2090-2582), and 
2290 (spa type t529, barcode 2110-3742). Also from the 
collection were two coagulase-negative strains such as 
S. simulans 3100-0949 and S. chromogenes 3140-3115 
that were used for antibacterial activity testing. The 
bacterial strains were maintained on tryptic soy agar 
or broth (TSA or TSB) as well as on mannitol salt agar 
(MSA), all from Becton–Dickinson (USA), and grown 
at 35 °C for 18–24 h.
Preparation of R. tomentosa leaf (RTL) extract 
and rhodomyrtone
The leaves of Rhodomyrtus tomentosa (Aiton) Hassk. 
were collected from the Singha Nakhon district, in the 
Songkhla province (Thailand) by Dr. Asadhawut Hiranrat 
(Department of Organic Chemistry, Faculty of Science, 
Prince of Songkla University). The voucher specimen 
(A. Hiranrat 001) was identified by J. Wei and has been 
deposited in the herbarium of Department of Biology, 
Faculty of Science, Prince of Songkla University, Thai-
land [22]. R. tomentosa leaves were dried in an oven at 
60  °C for 48  h and ground in an electric blender. Dried 
leaf powder was extracted with 95% ethanol at room tem-
perature and kept in the dark for 1 week. The extract was 
evaporated for 48 to 72 h by a rotary evaporator (BUCHI 
Rotavapor R-114, Büchai Labortechnik AG, Flawil, Swit-
zerland) until it was completely dry (visual inspection). 
The extract was then dissolved in dimethyl sulfoxide 
(DMSO, Sigma-Aldrich Inc., Oakville, Canada). Pure 
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rhodomyrtone (Sigma-Aldrich Inc.) was also dissolved in 
DMSO and kept at −20 °C until used.
Determination of the minimum inhibitory concentration 
(MIC) and minimum bactericidal concentration (MBC)
The minimum inhibitory concentrations (MICs) of the 
RTL extract, rhodomyrtone and other antibiotics were 
determined by a broth microdilution method according 
to the recommendations from the Clinical Laboratory 
Standards Institute (CLSI) for antimicrobial susceptibility 
testing [23]. The antibacterial agents, prepared in cation-
adjusted Mueller–Hinton broth (CAMHB, Becton–Dick-
inson, Mississauga, Canada) to a final concentration of 
256 µg/mL (highest concentration having ≤ 0.5% DMSO), 
were separately added and further diluted by twofold 
serial dilutions in 96-well plates. An equal volume of 
a bacterial suspension (~1 × 106 colony-forming units 
(CFU)/mL) was added to each well containing the anti-
bacterial agents and incubated at 35  °C for 18–24  h. In 
all assays, sterility and bacterial growth controls were 
included. Vancomycin (Sigma-Aldrich Inc.) and pirlimy-
cin hydrochloride  (Pirsue®, Zoetis Canada Inc., Kirkland, 
Canada) were included as reference drugs and for qual-
ity controls. The MIC was defined as the lowest concen-
tration of drug yielding no visible growth. The minimum 
bactericidal concentration (MBC) was determined subse-
quent to the MIC assay. A 10-µL aliquot from the visually 
clear wells containing the MIC value and higher concen-
trations were spread onto TSA plates. The agar plates 
were incubated at 35 °C for 18 h. The MBC was defined 
as the concentration killing 99.9% of the initial inocu-
lum. In some specified experiments, 5% casein (Sigma-
Aldrich Inc.) was added to CAMHB to mimic the milk 
environment.
Checkerboard assay and determination of the fractional 
inhibitory concentration (FIC) index
A two-dimensional broth microdilution checkerboard 
assay was performed to determine the MICs of the RTL 
extract or rhodomyrtone in combination with 10 antibi-
otics, including ampicillin, amoxicillin, penicillin, oxa-
cillin, ceftiofur, ciprofloxacin, gentamicin, kanamycin, 
pirlimycin, and oxytetracycline against S. aureus New-
bould. The antibiotics were serially diluted in the y-axis 
and the extract or rhodomyrtone in the x-axis. An equal 
volume of a bacterial suspension (~1 × 106 CFU/mL) was 
added to each well containing the antibacterial agents 
and incubated at 35  °C for 18–24 h. In all assays, steril-
ity and bacterial growth controls were included. The 
MIC was defined as the lowest concentration of drug 
(alone or in combination) yielding no visible growth. The 
antibacterial effect of each combination was determined 
by means of the FIC according to the following equation 
[24]:
The FIC index (∑FIC) was interpreted as follows: 
∑FIC ≤ 0.5, synergism; > 0.5–1, additivity; > 1–4, indif-
ference; ≥ 4, antagonism.
Kill kinetics
The bactericidal activity of the RTL extract and rho-
domyrtone against S. aureus was assessed by time-kill 
experiments. S. aureus Newbould and its isogenic ΔhemB 
mutant were used as representative strains for the wild-
type and SCV phenotype, respectively. The bacterial 
inoculum (~1 × 106 CFU/mL), as evaluated by turbidity 
using McFarland standards and confirmed by plating on 
agar for CFU counts, was grown with CAMHB supple-
mented with the plant ethanolic extract or rhodomyrtone 
at concentrations of 0.5×, 1×, 2×, and 4× their respec-
tive MIC value. The bacterial cultures were incubated at 
35 °C with shaking and their growth was monitored over 
24  h. Samples were collected at various time intervals 
followed by tenfold serial dilutions. A 10 µL aliquot was 
spread onto TSA plates for determination of the CFU. 
The bacterial growth kinetics was analyzed by plotting 
log 10 CFU/mL versus time.
Cell culture
Bovine mammary gland epithelial cells (MAC-T) were 
cultured in growth medium composed of Dulbecco’s 
Modified Eagle’s Medium (DMEM, Wisent Inc., Saint-
Jean-Baptiste, Canada) supplemented with 10% inacti-
vated fetal bovine serum (FBS, Wisent Inc.), 1% sodium 
pyruvate, 10  µg/mL insulin, 5  µg/mL hydrocortisone, 
100 units/mL penicillin, 100  µg/mL streptomycin, and 
0.025  µg/mL of fungizone. The cells were passaged 
twice a week up to ten passages after being thawed 
from the stock culture and incubated in 5%  CO2 at 
37  °C. A confluent monolayer of the cell culture was 
treated with a 0.25% trypsin solution (Wisent Inc.) for 
3–5  min and neutralized by adding DMEM supple-
mented with 10% FBS. Single cells were collected from 
the suspension after centrifugation using an Allegra™ 
6R centrifuge (Beckman Coulter Canada LP, Missis-
sauga, Canada) at 250 g, 25 °C, for 10 min. For specified 
FICA = MICcombination/MICA,
FICB = MICcombination/MICB,
∑
FIC = FICA + FICB
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experiments, aliquots of 250  µL of MAC-T cells were 
seeded into 24-well culture plates and incubated in the 
growth medium at 37 °C in a humidified incubator with 
5%  CO2, until the desired confluence was reached.
Cytotoxicity test
The cytotoxicity of the RTL extract, rhodomyrtone 
or pirlimycin for MAC-T cells was quantified using a 
lactate dehydrogenase (LDH) assay according to the 
manufacturer’s instructions (LDH Cytotoxicity detec-
tion kit, Roche Diagnostics GmbH, Mannheim, Ger-
many). The day before the experiment, the suspension 
of MAC-T cells was adjusted to 2 × 105 cells/mL in the 
growth medium and 250 µL of the cell suspension were 
added into 48-well tissue culture plates. The plates were 
incubated at 37  °C for 24  h in a humidified incubator 
with 5%  CO2 to obtain a confluent monolayer (~1 × 105 
cells/well). The cell monolayer was washed twice with 
DMEM and the growth medium was replaced with 
the assay medium (DMEM supplemented with 1% FBS 
without antibiotics) containing different concentra-
tions of the tested agents. A 1% triton X-100 solution 
(Sigma-Aldrich Inc.) and the assay medium itself were 
used as a high cytotoxicity control and the low cyto-
toxicity control, respectively. Cell-free supernatants 
were separately collected after treating for 8–12 h. An 
aliquot of 100  µL from each tested and control well 
were transferred to a 96-well plate, followed by adding 
100 µL of the LDH reaction mixture. The LDH reaction 
in each sample was measured by the optical density 
(OD) at 490  nm/660  nm using a spectrophotometric 
plate reader. The experiments were performed in trip-
licate. Percentage of cytotoxicity of antibacterial com-
pounds were determined and calculated according to 
the formula provided by the manufacturer, as follows:
Bacterial invasion assay
MAC-T cells were adjusted to 5 × 104 cells/mL with 
growth medium and 500  µL of the cell suspension was 
added into 24-well tissue culture plates. The plates were 
incubated at 37  °C for 48  h to obtain a >80% confluent 
monolayer (~1.5 × 105 cells/well). The cell monolayer 
was washed twice with DMEM, shielded with 500 µL of 
invasion medium (DMEM supplemented with 1% FBS 
without antibiotics), and re-incubated for 4  h. The cell 
monolayers were then washed with DMEM and the cell 
culture medium was replaced with 500 µL of the freshly 
Cytotoxicity(%) = [(OD of the tested cell mixture
−OD of the compound alone)
−OD low control]/
[(
OD high control − OD low control
)]
× 100
prepared bacterial suspension at a multiplicity of infec-
tion (MOI) of 10 or 100. Bacterial cell suspensions were 
prepared by adding an overnight culture of S. aureus into 
fresh TSB (1:20) containing ½ × MIC of the RTL extract 
or rhodomyrtone and incubated at 35  °C for 2  h. Van-
comycin (also at ½ × MIC) was used as the reference 
drug. All cultures contained 0.25% DMSO. These pre-
treated bacterial cells were then washed twice with cold 
sterile PBS and the bacterial suspension was adjusted 
to 3 × 106 CFU/mL in the invasion medium. After bac-
teria were added, each well was filled to 1 mL by adding 
500 µL of the test antibiotics at half its MIC. The plates 
were incubated at 37  °C for 3  h. Unattached and extra-
cellular bacteria were then removed from the monolay-
ers by washing twice with DMEM and possible residual 
extracellular bacteria were eliminated by adding 700  μL 
of 2 µg/mL lysostaphin (Sigma-Aldrich). The culture was 
further incubated for 30 min, therefore, the total incuba-
tion period was subsequently 3.5 h. After incubation, the 
cell monolayers were washed twice with D-PBS (Wisent 
Inc, Canada), trypsinized with 100  µL of trypsin solu-
tion for 10 min, and lysed with 900 µL of sterile distilled 
water for 5 min. The cell lysates were mixed thoroughly 
to release intracellular bacteria. The number of CFU was 
determined by the standard colony counting technique 
on TSA. Data are presented as the percentage of bacteria 
that were internalized relative to the initial bacterial sus-
pension exposed to MAC-T cells.
Efficacy in a mouse mastitis model
An in  vivo study was carried out using a mouse masti-
tis model according to the method described previously 
[25] with few modifications. Briefly, CD-1 lactating mice 
(Charles River, St-Constant, Canada) were used 12 to 
14 days after off spring birth. The pups were removed 1 h 
before challenged with 100 μL of S. aureus strain 2117 or 
Newbould (200  CFU/gland) via intramammary inocu-
lation in both the L4 (on the left) and R4 (on the right) 
abdominal mammary glands. Mammary glands were 
treated (intramammary administration) with the RTL 
extract (300 µg per dose, 2 doses to achieve maximal con-
centration), with pirlimicin (1 µg per dose) or a combina-
tion of both. For the extract, treatment was done at 0 and 
4 h post-infection, whereas pirlimycin was administered 
at 4 h. PBS was used for the untreated control. The mam-
mary glands were collected and homogenized at 16  h 
post-infection. The samples were serially diluted with 
PBS and plated on TSA and MSA for determination of 
the number of surviving bacteria. The data represent two 
independent experiments using several mice and glands 
in each. The animal experiments were conducted follow-
ing the guidelines of the Canadian Council on Animal 
Care and approved by the institutional ethics committee 
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on animal experimentation of the Faculté des sciences of 
Université de Sherbrooke.
Statistical analysis
In this study, the data were analyzed using the Graph-
Pad Prism Software (v.6.00). Tests used for the analysis of 
each experiment are specified in the figure legends.
Results
MIC and MBC of the RTL extract and rhodomyrtone
The RTL extract showed an antibacterial activity against 
a series of S. aureus and coagulase negative staphylo-
cocci (CNS) strains associated with bovine mastitis and 
had MIC values ranging from 8 to 16  μg/mL (Table  1). 
Noteworthy, the target strains included a S. aureus SCV 
(Newbould ΔhemB), a bovine MRSA and also a S. aureus 
of the spa type 13401 (strain 2117), producing a signifi-
cant amount of biofilm [21]. The inhibitory spectrum was 
similar to that of rhodomyrtone, which however exhib-
ited a stronger antibacterial activity with MIC values that 
ranged from 0.25 to 0.5 μg/mL. The pure compound pro-
vided inhibitory activity that was very close to the activ-
ity of vancomycin and pirlimycin, which had MIC values 
ranging from 0.25 to 1  μg/mL (Table  1). The MBCs of 
the RTL extract ranged from 16 to 128 μg/mL (i.e., 2–16 
times the MIC), whereas rhodomyrtone showed MBCs 
that were 1–4 times its MIC.
Kill kinetics
The kinetic of bacterial killing by the plant extract and 
rhodomyrtone was determined by following bacterial 
counts over 24 h. The agents were used at a sub-inhibitory 
concentration, at the MIC, and at supra-MICs against S. 
aureus Newbould (Figures 1A and C) and against its SCV 
Newbould ΔhemB (Figures 1B and D). The RTL extract at 
½ × MIC and 1 × MIC inhibited growth of the S. aureus 
by prolonging the bacterial lag phase. A strong bacteri-
cidal effect that decreased the number of viable bacterial 
cells by more than 3 log10 CFU/mL was observed using 
concentrations above the MIC against both strains within 
8  h (Figures  1A  and B). Treatment with rhodomyrtone 
showed almost identical kill kinetics than that of the RTL 
extract at the same multiples of its own MIC, although 
the concentrations used for the pure compound were 
much lower (Figures 1C and D).
Cytotoxicity
The RTL extract showed a relatively low cytotoxicity on 
MAC-T cells, which slowly increased in a concentration 
dependent manner (Table  2). This was similar to that 
observed with pirlimycin, which is abundantly used for 
the treatment of bovine mastitis. For the RTL extract, 
there was ~10–12% cytotoxicity at the MIC against S. 
aureus strains (i.e., 8–16  μg/mL). Interestingly, rho-
domyrtone was the least cytotoxic at concentrations of 
1–32 µg/mL but its cytotoxicity sharply increased to 42 
and 82% at concentrations of 64 and 128 µg/mL, respec-
tively (Table 2). Noteworthy, those concentrations of rho-
domyrtone represent 128 and 256 times, respectively, the 
MIC of this pure compound against S. aureus (Table 1). 
Note that, all antibacterial agents tested were diluted and 
tested in the presence of 3.2% DMSO (final concentra-
tion) and the solution of 3.2% DMSO that was used as 
an untreated control showed no toxicity on the MAC-T 
cell (i.e., no different than the no DMSO control; data not 
shown).
Inhibition of S. aureus internalization into MAC‑T cells
The number of bacteria internalized into MAC-T 
cells was first determined. As expected and shown 
before [7], at a MOI of 10 or 100, internalization of the 
Table 1 Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of the Rhodomyrtus 
tomentosa leaves (RTL) extract, rhodomyrtone, and reference antibiotics against staphylococcal strains 
Bacterial strains MIC/MBC (µg/mL)
RTL extract Rhodomyrtone Pirlimycin Vancomycin
Newbould (ATCC 29740) 16/128 0.5/0.5 0.5/1 0.5/1
Newbould ∆hemB (SCV) 8/16 0.5/1 0.25/0.5 0.5/1
S. aureus 1158c (bovine MRSA) 16/64 0.5/1 0.5/1 0.5/1
S. aureus SHY97-3906 8/16 0.5/1 0.5/1 0.5/1
S. aureus 2117 16/128 0.5/1 1/2 0.5/1
S. aureus 2236 16/64 0.5/1 1/2 0.5/1
S. aureus 2290 16/32 0.5/1 0.5/1 0.5/0.5
S. simulans 3100-0949 16/128 0.5/1 0.5/1 0.5/1
S. chromogenes 3140-3115 16/32 0.25/1 0.25/0.5 0.25/0.5
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Newbould SCV strain was always significantly greater 
than that of the prototypical Newbould strain (data not 
shown). For example, at a MOI of 10, approximately 
6 × 106 CFU/mL of the SCV strain were recovered from 
MAC-T cells after 3.5 h and these conditions were used 
to evaluate the inhibitory activity of the RTL extract on 
the internalization process. As shown in Figure  2, the 
presence of the RTL extract or the pure rhodomyrtone 
compound (both used at half their MIC) in the extra-
cellular milieu together with the SCV strain, reduced 
the number of internalized bacteria to approximately 
85 and 81% after 3.5  h, respectively, compared to that 
found for the untreated control (Figures  2A  and B). 
Vancomycin, also used at half its MIC, showed no 
significant reduction of the SCV numbers internal-
ized into MAC-T cells compared to the untreated 
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Figure 1 Time‑kill kinetics of the Rhodomyrtus tomentosa leaves (RTL) extract (A, B) and rhodomyrtone (C, D) against S. aureus Newbould 
(A, C) and its small‑colony variant (SCV, ΔhemB) (B, D). The data are expressed as means of three independent experiments. The detection limit 
was 100 CFU/mL.
Table 2 Cytotoxicity of the Rhodomyrtus tomentosa leaves 
(RTL) extract on MAC-T cells as determined by a LDH assay 
a The % cytotoxicity was calculated as described in “Materials and methods” 
section. Values are means of three independent experiments with standard 
deviations. All compounds were diluted and tested in presence of 3.2% DMSO 
(final concentration).
Concentration 
(µg/mL)
% cytotoxicity of antibacterial  agentsa
R. tomentosa extract Rhodomyrtone Pirlimycin
1 6.2 ± 1.4 0.2 ± 0.7 11.5 ± 1.4
2 6.9 ± 0.5 0.2 ± 0.2 14.4 ± 3.2
4 10.5 ± 0.6 0.2 ± 0.2 16.2 ± 1.3
8 10.9 ± 1.1 0.3 ± 0.5 18.9 ± 0.9
16 12.1 ± 0.04 0.4 ± 0.1 20.8 ± 0.5
32 12.7 ± 0.1 0.4 ± 0.3 23.5 ± 1.9
64 14.5 ± 1.8 42.2 ± 0.6 26.6 ± 3.0
128 16.4 ± 3.2 81.9 ± 3.2 28.3 ± 2.7
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control cells (Figures  2A  and B). Noteworthy, none of 
the antibacterial agents used here at half their MICs 
reduced the amounts of viable bacteria in the cell cul-
ture medium for an incubation period of 3.5  h in the 
absence of MAC-T cells or in the CAMHB medium as 
seen in time-kill kinetic assays (Figures 1B and D). The 
decrease in SCV internalization by the RTL extract or 
rhodomyrtone can therefore not be due to bacterial 
killing prior to internalization into MAC-T cells.
Benefits of compound combinations
In a checkerboard assay, multiple dilutions of 10 dif-
ferent antibiotics were combined with increasing con-
centrations of the RTL extract or rhodomyrtone, and 
a FIC index was determined for each tested combi-
nation against S. aureus Newbould for detection of 
possible synergy between some antibiotics and the 
natural products. For most antibiotics, no synergy was 
recorded. The exceptions were pirlimycin and oxytet-
racycline, which when combined with half the MIC of 
the RTL extract, the MIC of the antibiotic dropped by 
64 (oxytetracycline) to 128 (pirlimycin) times (Table 3). 
The resulting FIC index was ~0.5 (0.508–0.516), which 
technically depicts an additive effect at the limit of 
synergism (≤ 0.5). Rhodomyrtone, which is already as 
potent as most of the antibiotics tested did not show 
any synergy against that S. aureus strain (FIC index of 
1.01).
Since the RTL extract was bacteriostatic at half its 
MIC (Figures  1A  and B), the bactericidal activity of 
the RTL extract in combination with a fraction of the 
pirlimycin MIC was evaluated to see if the additive 
effect or weak synergy observed in the checkerboard 
assay translated into killing. Figure 3 shows indeed that 
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Figure 2 Effect of the Rhodomyrtus tomentosa leaves (RTL) extract (A) and rhodomyrtone (B) at half their minimal inhibitory 
concentrations (MICs) on the internalization of the small‑colony variant (SCV) strain Newbould ΔhemB into MAC‑T cells after a 3.5 h 
treatment. Vancomycin was also used as a control in each assay. The bars represent the means of three independent experiments with standard 
deviations. One-way analysis of variance was performed with Dunnett’s post-test: ***P = 0.0002; ****P = 0.0001; ns: not significant (P > 0.05).
Table 3 Minimal inhibitory concentrations (MICs, µg/mL) and the fractional inhibitory concentration index (∑FIC) of the 
Rhodomyrtus tomentosa leaves extract (RTLex) in combination with antibiotics (ATB) against S. aureus strain Newbould 
a MIC of the antibiotic (ATB) and MIC of the RTL extract (RTLex) when used alone.
b MIC of the ATB and MIC of the RTLex when used in combination.
c The fold improvement of the MIC is the ratio of the MIC alone/MIC in combination for the ATB or the RTLex.
d A ∑FIC of ≤ 0.5 is defined as synergism; 0.5–1 as additive; > 1–4 as indifference; > 4 as antagonism.
Antibiotic Individual  MICa
ATB/RTLex
MIC in  combinationb
ATB/RTLex
MIC fold  improvementc
ATB/RTLex
∑FICd
Pirlimycin 0.5/16 0.004/8 128/2 0.508
Oxytetracycline 0.5/16 0.008/8 64/2 0.516
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the combination of half the MIC of the RTL extract 
with 1/128 the MIC of pirlimycin kills significantly 
more than either of these agents used alone (P = 0.0002 
and P < 0.0001, respectively). These results show that 
the RTL extract could be employed to drastically reduce 
the useful concentration of an antibiotic like pirlimycin.
Efficacy of the RTL extract alone or in combination 
with pirlimycin in vivo
In vivo experiments were carried out to determine the 
therapeutic effects of the RTL extract, pirlimycin and 
a combination of both against a S. aureus challenge in 
the mouse mastitis model. The biofilm hyperproducing 
strain S. aureus 2117 was used for the challenge. The 
number of bacterial cells inside the mammary glands 
in the control condition (PBS treatment) reached a 
maximum of approximately 1 × 108 CFU/gland after 
16  h (Figure  4). The administration of the extract that 
was done twice (2 × 300 μg/gland) at 0 h and 4 h post-
infection did not significantly reduce the bacterial load 
when compared to the untreated control, although the 
bacterial counts in many of the treated glands showed 
lower CFU counts. On the other hand, the number of 
bacteria was significantly reduced (P < 0.001) to approx-
imately  106 CFU/gland by a treatment with pirlimycin 
(1  μg/gland at 4  h post-infection). Interestingly, there 
was an additional significant antibacterial effect when 
pirlimycin was used in combination with the RTL 
extract (P < 0.0001) when compared to the PBS con-
trol group. However, in those experimental conditions, 
there was no significant difference between treatment 
with pirlimycin alone or when in combination with the 
extract, although the bacterial counts in some of the 
glands treated with the combination reached the lowest 
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Figure 3 Bactericidal activity of sub‑inhibitory concentrations 
of the Rhodomyrtus tomentosa leaves extract (RTLex) and 
pirlimycin (PIR) used alone or in combination against S. aureus 
Newbould after 24 h. The bars represent the means of three 
independent experiments with standard deviations. Two-way ANOVA 
and Tukey’s multiple comparisons test: ****P < 0.0001; ***P = 0.0002; 
ns: not statistically significant (P > 0.05).
Figure 4 Bacterial colony‑forming unit (CFU) counts obtained 
from mice mammary glands 16 h post‑infection with S. 
aureus 2117. Mammary glands were treated (intra-mammary 
administration) with the Rhodomyrtus tomentosa leaves extract 
(RTLex: 300 µg per dose, 2 doses), with pirlimycin (PIR: 1 µg per dose), 
or a combination of both. For the extract, treatment was done at 0 
and 4 h post-infection, whereas pirlimycin was administered at 4 h. 
PBS was used for the controls (animals infected but not treated). 
Each dot represents the CFU of individual glands (n = 8–10) and 
the median value for each group is indicated by the bar. Statistical 
differences between CFUs recovered from treated and untreated 
animals are shown (non-parametric Kruskal–Wallis ANOVA with 
Dunn’s post-test: ***P < 0.001; ****P < 0.0001; ns: not statistically 
significant (P > 0.05) vs. untreated control).
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CFU counts (Figure  4). Almost identical results were 
obtained when mice were challenged with strain New-
bould (data not shown).
These results show that the RTL extract used at such a 
concentration and without any specific pharmacological 
formulation has some but limited activity in this mouse 
mastitis model. To that effect, we have determined the 
MIC of the RTL extract and of other antibiotics in the 
presence of 5% casein to mimic the milk environment. 
The results demonstrated that the addition of casein 
raised the MIC and MBC of the RTL extract since a four-
fold loss of the activity was observed (data not shown). 
On the other hand, pirlimycin showed no reduction of 
the activity in presence of casein.
Discussion
Considering that intramammary infections (IMIs) are 
responsible for most of the antibiotic use in dairy farms 
and that bacterial resistance to traditional antibiotics 
continues to progress and spread, the growing consumer 
concerns about food-related health risks have prompted 
the search for antibiotic alternatives for prevention and 
treatment of bovine mastitis. Since many medicinal 
plants have traditionally been used for remedy of some 
infectious diseases, plant extracts represent interesting 
sources of novel antibacterial substances.
In the present study, we are reporting the antibacte-
rial effects of an ethanolic extract of R. tomentosa leaves 
(RTL), a Thai traditional herbal plant, and of rhodo-
myrtone, a compound purified from this plant, against 
staphylococcal strains associated with bovine mastitis. 
The RTL extract and purified rhodomyrtone provided a 
strong antibacterial activity against staphylococci strains 
with MICs of 8–16 and 0.25–0.5  µg/mL, respectively, 
including against S. aureus SCV and MRSA strains. The 
MICs obtained in the present study can be advanta-
geously compared the other purified compounds from 
plant products or plant-derived antimicrobials. For 
instance, salvipisone, a diterpenoid compound isolated 
from the hairy roots of Salvia sclarea, has previously 
shown antibacterial activity against S. aureus and S. epi-
dermidis with MIC values ranging from 9.37 to 18.75 µg/
mL [26], whereas berberine, isolated from Coptidis rhi-
zome, exhibited a bacteriostatic effect on S. epidermidis 
strains with MICs of 64 to 256  µg/mL [27]. Another 
example is thymoquinone, an active principle found in 
Nigella sativa seeds, which showed MICs against Gram-
positive cocci (including S. aureus and S. epidermidis) 
ranging from 8 to 32 μg/mL [28].
Together with the growth inhibitory effect, other prop-
erties may be required from antibacterial substances 
in order to control pathogens like S. aureus, which pos-
sesses multiple strategies to colonize and persists in the 
bovine mammary gland. Here, we have also observed 
that the RTL extract and rhodomyrtone reduce internali-
zation of S. aureus into bovine epithelial mammary cells, 
and that the RTL extract can improve the activity of some 
traditional antibiotics. While the mechanisms underly-
ing such observations are yet to be identified, it is known 
that the RTL extract can affect the staphylococcal cells 
by increasing cell surface hydrophobicity in a concentra-
tion dependent manner [19]. Also, other pharmacologi-
cal activities of the RTL extract and rhodomyrtone have 
been evaluated and documented in previous studies. 
For instances, the plant extract displayed a strong anti-
biofilm forming effect against staphylococci [29], an anti-
quorum sensing activity against Streptococcus pyogenes 
[30], as well as anti-oxidative [31] and anti-inflammatory 
properties [32]. Moreover, rhodomyrtone can enhance 
the killing activities of human monocytes and induce 
the expression of local host immunity during S. aureus 
infections [33]. All of these RTL extract or rhodomyr-
tone properties may thus act synergistically to combat S. 
aureus infections.
The ease of production of the RTL extract compared to 
the steps required for the purification of rhodomyrtone 
was a major motivation for the realization of this study. 
Both, the extract and pure compound, have a similar 
antibacterial profile in terms of MIC/MBC ratios and 
spectrum of activity, in accordance to the fact that the 
RTL extract contains a diluted amount of rhodomyrtone. 
However, some interesting differences were observed as 
no synergy with antibiotics was found with pure rhodo-
myrtone. Also, the toxicity of the pure compound toward 
mammalian cells suddenly increased at a certain concen-
tration threshold but, for the extract, a more linear dose–
response effect was observed. While rhodomyrtone 
represents at least one of the bioactive compounds, the 
RTL extract likely contains other bioactive compounds 
which may contribute to the various antibacterial, anti-
oxidant and anti-inflammatory effects reported for the 
extract.
Experiments were carried out to determine the thera-
peutic effects of the RTL extract on S. aureus in a mouse 
mastitis model of infection. As sometimes seen with 
other natural products or extracts, the RTL extract was 
not as effective as expected in vivo and will likely need to 
be formulated to demonstrate its full antibacterial activ-
ity in a complex environment like the mammary gland. 
Many factors could have accounted for the low in  vivo 
efficacy, but we found that the presence of milk casein 
might be sufficient to reduce the antibacterial effect of 
the RTL extract, and this possibly through casein binding 
to active RTL components.
In summary, the extract and the pure compound 
could reduce the ability of S. aureus SCVs to invade and 
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survive intracellularly as shown by the reduced num-
ber of bacteria found inside bovine mammary epithe-
lial cells after treatment. Moreover, a sub-MIC of the 
extract demonstrated an improved bactericidal activ-
ity when in combination with a sub-MIC of pirlimycin 
against S. aureus in  vitro. While a proper pharmaco-
logical formulation would seem to be required to reveal 
the full activity of the RTL extract in  vivo, our work 
show promising results that could qualify the extract as 
a possible natural alternative to traditional antibiotics 
or at the least as an agent that could help reduce antibi-
otic use in dairy farms. This view is in agreement with 
the conclusions of the  2nd International Symposium 
on Alternatives to Antibiotics, which were recently 
reviewed by Lillehoj et al. [34] and which highlight the 
potential role and importance of phytochemicals in the 
global efforts aimed at reducing antibiotic use in animal 
productions.
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